Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Tazemetostatum, [1, 1′-Biphenyl]-3-carboxamide, N-[(1, 2-dihydro-4 and 6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4′-(4-morpholinylmethyl)-. Its PubChem CID is 66558664.
Tazemetostat
| CAS No | 1403254-99-8 |
|---|---|
| Molecular Formula | C34H44N4O4 |
| Molecular Weight | 572.7 g/mol |
| Synonyms | N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Its therapeutic use is listed as anti-cancer agents.
The listed CAS number is 1403254-99-8.
The listed molecular formula is C34H44N4O4.
The listed molecular weight is 572.7 g/mol.
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide.
The source lists Tazemetostatum, [1, 1'-Biphenyl]-3-carboxamide, N-[(1, 2-dihydro-4 and 6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-.